MELVILLE, N.Y., Jan. 20, 2016 /PRNewswire/ -- Focusing on targets
relevant to researchers, Canon BioMedical is excited to announce
the addition of 72 new assays to the Novallele genotyping
library. Included in this expansion are two novel assays, MELAS
m.3243A>G Novallele Genotyping Assay and LHON m.11778G>A
Novallele Genotyping Assay, that detect mutations in mitochondrial
DNA. Providing scientists a fast and simple method to detect
single-nucleotide polymorphisms (SNPs), these assays distinguish
mutations that may play a role in mitochondrial disease.
Mitochondrial diseases are hard to identify because they affect
individuals differently. Simple and easy diagnosis options are
currently unavailable, and those afflicted undergo intense and
extensive examination to receive a diagnosis. The new assays
offered by Canon BioMedical support researchers and their objective
of understanding the genetic basis of these complex diseases. The
new MELAS m.3243A>G Novallele Genotyping Assay detects a SNP of
the MELAS gene, which may play a role in the MELAS disorder.
Additionally, the LHON m.11778G>A Novallele Genotyping Assay
detects a SNP of the LHON gene, which may play a role in Leber
hereditary optic neuropathy (LHON).
The Novallele genotyping assays detect genetic variations using
polymerase chain reaction (PCR) followed by high-resolution melting
(HRM) analysis on any thermocycler capable of HRM. All Novallele
genotyping assays are functionally verified and focus on relevant
genotypes to genetic researchers working to improve health and
advance science.
"After launching our first assays in September, we continue to
actively understand and focus on areas of discovery that are
challenging for researchers," shares Akiko
Tanaka, president and CEO of Canon BioMedical. "Our goal is
to develop genotyping tools that address all types of genetic
variation pertinent to human health, and our assays detecting
mitochondrial DNA mutations exemplify our capabilities to help
researchers with this type of genetic research."
Full details about these new products are available at
www.canon-biomedical.com. In addition, Canon BioMedical will
present the expanded Novallele genotyping library at the American
College of Human Genetics in Tampa,
Florida on March 9 as well as
the Molecular Medicine Tri-Conference in San Francisco, California on March 8.
About Canon BioMedical, Inc.
Canon BioMedical, Inc., a wholly owned subsidiary of Canon
U.S.A., Inc., is focused on
empowering the biomedical research and healthcare communities by
developing, manufacturing, and marketing innovative technologies
and solutions. The technologies and solutions developed will help
enable clinicians and scientists to improve our health and advance
science. Canon BioMedical will continue to pursue innovative
solutions in line with Canon's Kyosei philosophy of social
and environmental responsibility through the use of existing and
emerging Canon technology as well as strategic partnerships.
Products mentioned in this release are for Research Use Only.
Not for use in diagnostic procedures.
All referenced product names, and other marks, are trademarks of
their respective owners.
Logo - http://photos.prnewswire.com/prnh/20160119/323578LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/canon-biomedical-expands-assays-to-support-genetic-researchers-300207032.html
SOURCE Canon BioMedical, Inc.